explore -WSS

explore

author：focus 2025-09-28 02:31:18 - browse：3785

Light micrograph of a fatty liver — Large vacuoles of triglyceride fat, accumulated inside liver cells. Adobe

SAN DIEGO — An experimental obesity drug from Eli Lilly significantly reduced liver fat in a small analysis, supporting further studies of the treatment against nonalcoholic fatty liver disease, an increasingly common condition that lacks approved treatments.

Among 98 patients with nonalcoholic fatty liver disease, those on the highest dose tested of the drug, retatrutide, experienced an 86% decrease in liver fat over 48 weeks, with most of the reduction occurring early on in treatment, according to data presented here at the American Diabetes Association conference Monday.

Additionally, 93% of people on the highest dose achieved resolution of fatty liver disease, defined as having 5% or less liver fat.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： The mammogram wars are not over

WSS

Readout Newsletter: Biogen, Rocket Pharma, KalVista, and more

BioAge raises $170M for combination therapy with Zepbound

Medicare Advantage proposed rates disappoint insurers

Ford recalls 870K F

What we’ve learned from the Aduhelm mess

Moscow blames Kyiv for missile attacks in southern Russia as Kremlin forces pound Ukrainian village

leisure time

explore

knowledge

Virginia high school admissions case could be legal follow

A disappointing year of Humira biosimilars

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

McConnell had minor fall 2 weeks ago, uses wheelchair periodically to get around: Sources

Malaria cases in Florida and Texas: Here’s what you need to know

Medicare threatens to cut off funding for HCA's Mission hospital

At least 13 dead in Texas as scorching temps continue

Stoke drug shows lower activity against childhood epilepsy

Wildfire smoke exposes gaps in outdoor worker protections

An outrageous hospital charge: I paid $710 for an hour of babysitting

focus

Ford recalls 870K F

Biden to sign 'historic' executive order on how US military handles sexual assault cases

The dental labor crisis is a moment of opportunity

The Readout: Gilead, Bernie Sanders, and other pharma news

Biogen Alzheimer’s drug launch off to slow start

Readout Newsletter: Biogen, Rocket Pharma, KalVista, and more

hotspot

entertainment

entertainment

hotspot